AI assistant
Sarepta Therapeutics, Inc. — Director's Dealing 2021
Mar 6, 2021
31721_dirs_2021-03-05_72c5d1d2-4c5b-4cdf-9961-86647ff6a9b2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Sarepta Therapeutics, Inc. (SRPT)
CIK: 0000873303
Period of Report: 2021-03-03
Reporting Person: Estepan Ian Michael (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-03 | Common Stock | A | 15000 | $0.00 | Acquired | 29042 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-03 | Stock Option (right to buy) | $87.11 | A | 60000 | Acquired | 2031-03-03 | Common Stock (60000) | Direct |
Footnotes
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date.
F2: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.